We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE)

Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) is a biotechnology company specializing in clinical ... read more Featured Products: More products

Download Mobile App





SNIBE Displays Super High Throughput CLIA Analyzer Powered by X Tech Technology

By LabMedica International staff writers
Posted on 21 May 2023
Print article
Image: The MAGLUMI X series CLIA analyzers is powered by X Tech technology (Photo courtesy of Snibe)
Image: The MAGLUMI X series CLIA analyzers is powered by X Tech technology (Photo courtesy of Snibe)

Snibe (Shenzhen, China) is showcasing its latest products with high-performance features at Euromedlab Roma 2023, including the newest member of its X-series of new-generation chemiluminescence immunoassay (CLIA) analyzers.

MAGLUMI X Tech is the core technology powering the X series of fully automatic CLIA analyzers which provide more efficient, convenient, and reliable immunology diagnostic solutions for laboratories and hospitals. The technology helps the X series analyzers deliver an amazing performance, higher accuracy, and further precision, while also making them affordable and easy to operate. The MAGLUMI X series offers three models to meet all types of demands. The small but smart MAGLUMI X3 is a small-footprint desktop analyzer having a throughput of 200 t/h, 20 reagent positions, and 72 sample positions to target for small- and mid-size laboratories and hospitals.

The most cost-effective analyzer and the newest member of the X-series - MAGLUMI X6 - with a higher throughput of up to 450 T/h offers up to 30 reagent positions and up to 112 sample positions, or up to 412 when integrated with a sample-storage module. The fastest analyzer in the X series - MAGLUMI X8 - is the most powerful CLIA analyzer that offers a super-high throughput of 600 t/h while ensuring the highest level of precision. It offers 42 reagent positions and 300 sample positions. MAGLUMI X8 can be integrated with the Biossays C8 to create the Biolumi CX8 biochemical and immunological integrated analyzer.

Aided by the incredible X Tech, the MAGLUMI X series CLIA analyzers possess even more powerful capabilities such as patented pipetting technology, accurate incubation technology, stable and precise measuring technology, multiple expansion solutions, and user-friendly and high-efficiency loading design. These latest high-end features help the MAGLUMI X series CLIA analyzers to provide better immunology diagnostic capabilities for laboratories and hospitals.

Related Links:
Snibe 

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
AESKULISA tTg-A New Generation
New
HSV-1 Test
Herpes Simplex Virus 1 Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.